Anthrax

New England Journal of Medicine

Volumn 341, Issue 11, 1999, Pages 815-826

  Dixon, Terry C ^a   Meselson, Matthew ^b   Guillemin, Jeanne ^c   Hanna, Philip C ^a,d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HARVARD UNIVERSITY   (United States)

^c BOSTON COLLEGE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; DEXAMETHASONE; DOXYCYCLINE; ERYTHROMYCIN LACTOBIONATE; PENICILLIN G; PENICILLIN V; PREDNISONE; STREPTOMYCIN; TETRACYCLINE;

ANTHRAX; BACILLUS ANTHRACIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; HUMAN; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANTHRAX; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; DIAGNOSIS, DIFFERENTIAL; GASTROINTESTINAL DISEASES; GLUCOCORTICOIDS; HUMANS; MEDIASTINAL DISEASES; MENINGITIS, BACTERIAL; MOUTH DISEASES; PHARYNGEAL DISEASES; SKIN DISEASES, BACTERIAL; VIRULENCE;

EID: 0033539028     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199909093411107     Document Type: Review

References (130)

1. Hanna P. Anthrax pathogenesis and host response. Curr Top Microbiol Immunol 1998;225:13-35.
2. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994;266:1202-8.
3. Hanna PC, Acosta D, Collier RJ. On the role of macrophages in anthrax. Proc Natl Acad Sci U S A 1993;90:10198-201.
4. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management. JAMA 1999;281:1735-45.
5. Watson A, Keir D. Information on which to base assessments of risk from environments contaminated with anthrax spores. Epidemiol Infect 1994;113:479-90.
6. Harris SH. Factories of death: Japanese secret biological warfare, 1932-1945, and the American cover-up. London: Routledge, 1994.
7. Ross JM. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol 1957;73:485-94.
8. Guidi-Rontani C, Weber-Levy M, Labruyere E, Mock M. Germination of Bacillus anthracis spores within alveolar macrophages. Mol Microbiol 1999;31:9-17.
9. Leppla SH. The anthrax toxin complex. In: Alouf J, Freer JH, eds. Sourcebook of bacterial protein toxins. London: Academic Press, 1991: 277-302.
10. Idem. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci USA 1982;79:3162-6.
11. Idem. Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells. Adv Cyclic Nucleotide Protein Phosphorylation Res 1984;17:189-98.
12. O'Brien J, Friedlander A, Dreier T, Ezzell J, Leppla S. Effects of anthrax toxin components on human neutrophils. Infect Immun 1985;47:306-10.
13. Alexeyev OA, Morozov VG, Suzdaltseva TV, Mishukov AS, Steinberg LA. Impaired neutrophil function in the cutaneous form of anthrax. Infection 1994;22:281-2.
14. Hammond SE, Hanna PC. Lethal factor active-site mutations affect catalytic activity in vitro. Infect Immun 1998;66:2374-8.
15. Hanna PC, Kruskal BA, Ezekowitz RA, Bloom BR, Collier RJ. Role of macrophage oxidative burst in the action of anthrax lethal toxin. Mol Med 1994;1:7-18.
16. Klimpel KR, Arora N, Leppla SH. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol Microbiol 1994;13:1093-100.
17. Duesbery NS, Webb CP, Leppla SH, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998;280:734-7.
18. Vitale G, Pellizzari R, Recchi C, Napolitani G, Mock M, Montecucco C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem Biophys Res Commun 1998;248:706-11.
19. Hanna PC, Kochi S, Collier RJ. Biochemical and physiological changes induced by anthrax lethal toxin in J774 macrophage-like cells. Mol Biol Cell 1992;3:1269-77.
20. Makino S-I, Uchida I, Terakado N, Sasakawa C, Yoshikawa M. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J Bacteriol 1989;171:722-30.
21. 2-dependent expression of the genetic region for encapsulation from Bacillus anthracis. Mol Microbiol 1988;2:371-6.
22. Dai Z, Sirard J-C, Mock M, Koehler TM. The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence. Mol Microbiol 1995;16:1171-81.
23. Dai Z, Koehler TM. Regulation of anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis. Infect Immun 1997;65:2576-82.
24. Uchida I, Hornung JM, Thorne CB, Klimpel KR, Leppla SH. Cloning and characterization of a gene whose product is a trans-activator of anthrax toxin synthesis. J Bacteriol 1993;175:5329-38.
25. Uchida I, Makino S, Sekizaki T, Terakado N. Cross-talk to the genes for Bacillus anthracis capsule synthesis by atxA, the gene encoding the trans-activator of anthrax toxin synthesis. Mol Microbiol 1997;23:1229-40.
26. Vietri NJ, Marrero R, Hoover TA, Welkos SL. Identification and characterization of a trans-activator involved in the regulation of encapsulation by Bacillus anthracis. Gene 1995;152:1-9.
27. Taylor JP, Dimmitt DC, Ezzell JW, Whitford H. Indigenous human cutaneous anthrax in Texas. South Med J 1993;86:1-4.
28. Human cutaneous anthrax - North Carolina, 1987. Arch Dermatol 1988;124:1324.
29. Leads from the MMWR: human cutaneous anthrax - North Carolina, 1987. JAMA 1988;260:616.
30. Human cutaneous anthrax - North Carolina, 1987. MMWR Morb Mortal Wkly Rep 1988;37:413-4.
31. Bradaric N, Punda-Polic V. Cutaneous anthrax due to penicillin-resistant Bacillus anthracis transmitted by an insect bite. Lancet 1992;340:306-7.
32. Turell MJ, Knudson GB. Mechanical transmission of Bacillus anthracis by stable flies (Stomoxys calcitrans) and mosquitoes (Aedes aegypti and Aedes taeniorhynchus). Infect Immun 1987;55:1859-61.
33. Smego RA Jr, Gebrian B, Desmangels G. Cutaneous manifestations of anthrax in rural Haiti. Clin Infect Dis 1998;26:97-102.
34. Edwards MS. Anthrax. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases. 3rd ed. Vol. 1. Philadelphia: W.B. Saunders, 1992:1053-6.
35. Doganay M, Bakir M, Dokmetas I. A case of cutaneous anthrax with toxaemic shock. Br J Dermatol 1987;117:659-62.
36. Kutluk MT, Secmeer G, Kanra G, Celiker A, Aksoyek H. Cutaneous anthrax. Cutis 1987;40:117-8.
37. Doganay M, Aygen B, Inan M, Kandemir O, Turnbull P. Temporal artery inflammation as a complication of anthrax. J Infect 1994;28:311-4.
38. Yorston D, Foster A. Cutaneous anthrax leading to corneal scarring from cicatricial ectropion. Br J Ophthalmol 1989;73:809-11.
39. Mallon E, McKee PH. Extraordinary case report: cutaneous anthrax. Am J Dermatopathol 1997;19:79-82.
40. LaForce FM. Anthrax. Clin Infect Dis 1994;19:1009-14.
41. de Lalla F, Ezzell JW, Pellizzer G, et al. Familial outbreak of agriculture anthrax in an area of northern Italy. Eur J Clin Microbiol Infect Dis 1992;11:839-42.
42. Batykin V, Vygodchikov G, Sazshina Y. Outbreak of intestinal anthrax in Yarolslavl. J Hyg Epidemiol 1929;1:25-30.
43. Dutz W, Kohout E. Anthrax. Pathol Annu 1971;6:209-48.
44. Dutz W, Saidi F, Kohout E. Gastric anthrax with massive ascites. Gut 1970;11:352-4.
45. Dutz W, Kohout-Dutz E. Anthrax. Int J Dermatol 1981;20:203-6.
46. Nalin DR, Sultana B, Sahunja R, et al. Survival of a patient with intestinal anthrax. Am J Med 1977;62:130-2.
47. Paulet R, Caussin C, Coudray JM, Selcer D, de Rohan Chabot P. Forme viscérale de charbon humain importée d'Africa. Presse Med 1994; 23:477-8.
48. Alizad A, Ayoub EM, Makki N. Intestinal anthrax in a two-year-old child. Pediatr Infect Dis J 1995;14:394-5.
49. Dahlgren CM, Buchanan LM, Decker HM, Freed SW, Phillips CR, Brachman PS. Bacillus anthracis aerosols in goat hair processing mills. Am J Hyg 1960;72:24-31.
50. Albrink WS, Brooks SM, Biron RE, Kopel M. Human inhalation anthrax: a report of three fatal cases. Am J Pathol 1960;36:457-71.
51. Brachman PS, Kaufman AF, Dalldorf FG. Industrial inhalation anthrax. Bacteriol Rev 1966;30:646-59.
52. Manchee RJ, Broster MG, Henstridge RM, Stagg AJ, Melling J. Anthrax island. Nature 1982;296:598.
53. Manchee RJ. Bacillus anthracis on Gruinard Island. Nature 1981;294: 254-5.
54. Sterne M. Anthrax island. Nature 1982;295:362.
55. Wynn J. Anthrax island: why worry? Nature 1982;298:506-7.
56. Jackson PJ, Hugh-Jones ME, Adair DM, et al. PCR analysis of tissue samples from the 1979 Sverdlovsk anthrax victims: the presence of multiple Bacillus anthracis strains in different victims. Proc Natl Acad Sci U S A 1998;95:1224-9.
57. Guillemin J. Anthrax: the investigation of a deadly outbreak. Berkeley: University of California Press (in press).
58. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 1993;90:2291-4.
59. Penn CC, Klotz SA. Anthrax pneumonia. Semin Respir Infect 1997; 12:28-30.
60. Brachman PS. Inhalation anthrax. Ann N Y Acad Sci 1980;353:83-93.
61. Idem. Anthrax. Ann N Y Acad Sci 1970;174:577-82.
62. Albrink WS. Pathogenesis of inhalation anthrax. Bacteriol Rev 1961; 25:268-73.
63. Friedlander AM, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalation anthra. J Infect Dis 1993;167:1239-43.
64. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg 1956;54: 28-36.
65. Tahernia AC, Hashemi G. Survival in anthrax meningitis. Pediatrics 1972;50:329-33.
66. Tabatabaie P, Syadati A. Bacillus anthracis as a cause of bacterial meningitis. Pediatr Infect Dis J 1993;12:1035-7.
67. Tahernia AC. Treatment of anthrax in children. Arch Dis Child 1967; 42:181-2.
68. Rangel RA, Gonzalez DA. Bacillus anthracic meningitis. Neurology 1975;25:525-30.
69. Pluot M, Vital C, Aubertin J, Croix JC, Pire JC, Poisot D. Anthrax meningitis: report of two cases with autopsies. Acta Neuropathol (Berl) 1976;36:339-45.
70. Aksaray N, Cinaz P, Coskun U, Serbest M, Koksal F. Cutaneous anthrax. Trop Geogr Med 1990;42:168-71.
71. Wheat J. Histoplasma. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. 2nd ed. Philadelphia: W.B. Saunders, 1998:2335-44.
72. Claus D, Berkeley RCW. Genus Bacillus. In: Sneath PHA, ed. Bergey's manual of systematic bacteriology. Vol. 2. Baltimore: Williams & Wilkins, 1986:1105-39.
73. Turnbull PCB, Kramer JM. Bacillus. In: Balows A, ed. Manual of clinical microbiology. 5th ed. Washington, D.C.: American Society for Microbiology, 1991:296-303.
74. Penn CC, Klotz SA. Bacillus anthracis and other aerobic spore formers. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. 2nd ed. Philadelphia: W.B, Saunders, 1998:1747-50.
75. Parry JM, Turnbull PCB, Gibson JR. A color atlas of Bacillus species. London: Wolfe Medical, 1983:272.
76. Green BD, Battisti L, Koehler TM, Thorne CB, Ivins BE. Demonstration of a capsule plasmid in Bacillus anthracis. Infect Immun 1985;49:291-7.
77. Penn CC, Klotz SA. Anthrax. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. 2nd ed. Philadelphia: W.B. Saunders, 1998: 1575-8.
78. Gold H. Treatment of anthrax. Fed Proc 1967;26:1563-8.
79. Knisely RF. Selective medium for Bacillus anthracis. J Bacteriol 1966; 92:784-6.
80. Logan NA, Carman JA, Melling J, Berkeley RCW. Identification of Bacillus anthracis by API tests. J Med Microbiol 1985;20:75-85.
81. Shlyakhov E, Rubinstein E. Evaluation of the anthraxin skin test for diagnosis of acute and past human anthrax. Eur J Clin Microbiol Infect Dis 1996;15:242-5.
82. Lalitha MK, Thomas MK. Penicillin resistance in Bacillus anthracis. Lancet 1997;349:1522.
83. Harrison LH, Ezzell JW, Abshire TG, Kidd S, Kaufmann AF. Evaluation of serologic tests for diagnosis of anthrax after an outbreak of cutaneous anthrax in Paraguay. J Infect Dis 1989;160:706-10.
84. Turnbull PC, Doganay M, Lindeque PM, Aygen B, McLaughlin J. Serology and anthrax in humans, livestock and Etosha National Park wildlife. Epidemiol Infect 1992;108:299-313.
85. Sirisanthana T, Nelson KE, Ezzell JW, Abshire TG. Serological studies of patients with cutaneous and oral-oropharyngeal anthrax from northern Thailand. Am J Trop Med Hyg 1988;39:575-81.
86. Johnson-Winegar A. Comparison of enzyme-linked immunosorbent and indirect hemagglutination assays for determining anthrax antibodies. J Clin Microbiol 1984;20:357-61.
87. Pfisterer RM. Eine Milzbrandepidemie in der Schweiz: Klinische, diagnostische und epidemiologische Aspekte einer weitgehend vergessenen Krankheit. Schweiz Med Wochenschr 1991;121:813-25.
88. Shlyakhov E, Rubinstein E, Novikov I. Anthrax post-vaccinal cell-mediated immunity in humans: kinetics pattern. Vaccine 1997;15:631-6.
89. Andersen GL, Simchock JM, Wilson KH. Identification of a region of genetic variability among Bacillus anthracis strains and related species. J Bacteriol 1996;178:377-84.
90. Patra G, Vaissaire J, Weber-Levy M, Le Doujet C, Mock M. Molecular characterization of Bacillus strains involved in outbreaks of anthrax in France in 1997. J Clin Microbiol 1998;36:3412-4.
91. Patra G, Sylvestre P, Ramisse V, Therasse J, Guesdon JL. Isolation of a specific chromosomic DNA sequence of Bacillus anthracis and its possible use in diagnosis. FEMS Immunol Med Microbiol 1996;15:223-31.
92. Ramisse V, Patra G, Garrigue H, Guesdon JL, Mock M. Identification and characterization of Bacillus anthracis by multiplex PCR analysis of sequences on plasmids pXO1 and pXO2 and chromosomal DNA. FEMS Microbiol Lett 1996;145:9-16.
93. Keim P, Kalif A, Schupp J, et al. Molecular evolution and diversity in Bacillus anthracis as detected by amplified fragment length polymorphism markers. J Bacteriol 1997;179:818-24.
94. Klevytskya A, Schupp J, Price LB, et al. A multiplexed fluorescent PCR genotyping system based on ten highly informative single-locus markers for B. anthracis strain identification. Presented at the Third International Conference on Anthrax, Plymouth, England, 1998. abstract.
95. Price LB, Hugh-Jones M, Jackson PJ, Keim P. Genetic diversity in the protective antigen gene of Bacillus anthracis. J Bacteriol 1999;181:2358-62.
96. Jackson PJ, Walthers EA, Kalif AS, et al. Characterization of the variable-number tandem repeats in vrrA from different Bacillus anthracis isolates. Appl Environ Microbiol 1997;63:1400-5.
97. Vancurik J. Causes of the failure of antibiotic prophylaxis of inhalation anthrax and clearance of the spores from the lungs. Folia Microbiol (Praha) 1966;11:459-64.
98. Vaccine against anthrax. BMJ 1965;5464:717-8.
99. Anthrax vaccine. Med Lett Drugs Ther 1998;40:52-3.
100. Ivins BE, Fellows P, Pitt ML, et al. Efficacy of standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. Salisbury Med Bull 1996;87:125-6.
101. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field evaluation of a human anthrax vaccine. Am J Public Health 1962;52:632-45.
102. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997;278:399-411.
103. Shlyakhov EN, Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine 1994;12:727-30.
104. Pezard C, Weber M, Sirard JC, Berche P, Mock M. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect Immun 1995;63:1369-72.
105. Pezard C, Sirard JC, Mock M. Protective immunity induced by Bacillus anthracis toxin mutant strains. Adv Exp Med Biol 1996;397:69-72.
106. Miller J, McBride BW, Manchee RJ, Moore P, Baillie LW. Production and purification of recombinant protective antigen and protective efficacy against Bacillus anthracis. Lett Appl Microbiol 1998;26:56-60.
107. Little SF, Knudson GB. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun 1986;52:509-12.
108. Ivins BE, Welkos SL, Knudson GB, Little SF. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect Immun 1990;58:303-8.
109. Ivins BE, Welkos SL, Little SF, Crumrine MH, Nelson GO. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect Immun 1992;60:662-8.
110. Ivins BE, Fellows PF, Nelson GO. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs. Vaccine 1994;12:872-4.
111. Coulson NM, Fulop M, Titball RW. Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge. Vaccine 1994;12:1395-401.
112. Baillie L, Moir A, Manchee R. The expression of the protective antigen of Bacillus anthracis in Bacillus subtilis. J Appl Microbiol 1998;84: 741-6.
113. Baillie LW, Moore P, McBride BW. A heat-inducible Bacillus subtilis bacteriophage phi 105 expression system for the production of the protective antigen of Bacillus anthracis. FEMS Microbiol Lett 1998;163:43-7.
114. Hanna P. How anthrax kills. Science 1998;280:1671, 1673-4.
115. Young LS, Feeley JC, Brachman PS. Vaporized formaldehyde treatment of a textile mill contaminated with Bacillus anthracis. Arch Environ Health 1970;20:400-3.
116. Manchee RJ, Broster MG, Stagg AJ, Hibbs SE. Formaldehyde dilution effectively inactivates spores of Bacillus anthracis on the Scottish island of Gruinard. Appl Environ Microbiol 1994;60:4167-71.
117. Birensvige A. Inhalation hazard from reaerosolized biological agents: a review. Aberdeen, Md.: Army Chemical Research, Development and Engineering Center, 1992.
118. Davids DE, Lejeune AR. Secondary aerosol hazard in the field. Raulston, Alta.: Suffield Defence Research Establishment, 1981.
119. Knudson GB. Treatment of anthrax in man: history and current concepts. Mil Med 1986;151:71-7.
120. Doust JY, Sarkarzadeh A, Kavoossi K. Corticosteroid in treatment of malignant edema of chest wall and neck (anthrax). Dis Chest 1968;53:773-4.
121. Cataldi A, Labruyere E, Mock M. Construction and characterization of a protective antigen-deficient Bacillus anthracis strain. Mol Microbiol 1990;4:1111-7.
122. Pezard C, Berche P, Mock M. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immun 1991;59:3472-7.
123. Turnbull PC, Leppla SH, Broster MG, Quinn CP, Melling J. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol (Berl) 1988;177:293-303.
124. Dirckx JH. Virgil on anthrax. Am J Dermatopathol 1981;3:191-5.
125. Koch R. The aetiology of anthrax based on the ontogeny of the anthrax bacillus. Beitr Biol Pflanz 1877;2:277-82.
126. Pasteur L. De l'atténuation des virus et de leur retour à la virulence. C R Acad Sci III 1881;92:429-35.
127. Metchnikoff E. Immunity in infective diseases. Cambridge, England: Cambridge University Press, 1905.
128. Ember LR. Bioterrorism: combating the threat. Chem Eng News 1999;77:8-17.
129. Bioterrorism alleging use of anthrax and interim guidelines for management - United States, 1998. MMWR Morb Mortal Wkly Rep 1999; 48:69-74.
130. Pomerantsev AP, Staritsin NA, Mockov Yu V, Marinin LI. Expression of cereolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine 1997;15: 1846-50.